Stockscreener 앱 받기
16.04
1.72%
-0.28
시장 영업 전:
15.98
-0.06
-0.37%
Viatris Inc 주식(VTRS)의 최신 뉴스
Viatris launches €650M 4.250% senior notes due 2033 offering - TradingView
Viatris (VTRS) prices €650M 4.250% senior notes maturing 2033 - Stock Titan
Euro Bond Sale Might Change The Case For Investing In Viatris (VTRS) - simplywall.st
Viatris Inc. (VTRS) Stock Analysis: Navigating Growth Prospects with an 8.09% Potential Upside - DirectorsTalk Interviews
Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns - Yahoo Finance
Viatris Euro Debt Raise Reshapes Capital Structure And Valuation Story - Yahoo Finance
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
[424B5] Viatris Inc Prospectus Supplement (Debt Securities) - Stock Titan
A Look at Viatris Inc (VTRS) After 3.4% Gain -- GF Value $11.01 vs Price $16.31 - GuruFocus
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.70% Potential Upside with a Strong Dividend Yield - DirectorsTalk Interviews
Viatris (VTRS) Holds Steady Near Support Amid Flat Trading SessionRSI Overbought Alerts - newsline.com
Liquidity Mapping Around (VTRS) Price Events - Stock Traders Daily
FDA accepts Viatris' NDA for fast-acting non-opioid pain therapy - MSN
Investors brace for Viatris earnings as CFO departure looms By Investing.com - Investing.com Nigeria
Here's Why Viatris (VTRS) is a Strong Value Stock - Yahoo Finance
Salesforce : Agentforce Life Sciences Selected by Viatris as Its Global Customer Engagement Platform - marketscreener.com
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring An 11% Potential Upside Amid Mixed Metrics - DirectorsTalk Interviews
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Does FDA Review of Fast-Acting Meloxicam Shift Viatris’ (VTRS) Non-Opioid Pain Strategy? - simplywall.st
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris Top Brass Sued by Investor Over India Facility Problems - Bloomberg Law News
Argus Raises Viatris Price Target to $18 From $15 - Moomoo
Why (VTRS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Analyst Report Highlights Viatris Inc’s Strategic Positioning Amid Generic Drug CompetitionLow Estimate Range - newsline.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris (VTRS) Under Pressure: Support Levels Tested After 1.5% DeclineVolatility Smile - newsline.com
Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035 - GlobeNewswire Inc.
Viatris Inc. (VTRS) Stock Analysis: Investor Outlook on a Healthcare Giant with an 8.44% Upside Potential - DirectorsTalk Interviews
Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid Meloxicam - Yahoo Finance
What Viatris (VTRS)'s Fast-Acting Pain Drug Filing and Profit Uptick Means For Shareholders - simplywall.st
Viatris Inc.: - marketscreener.com
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Viatris (VTRS) price target increased by 10.47% to 17.48 - MSN
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
VTRS Maintains Overweight Rating -- Price Target Raised to $22 - GuruFocus
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy - Yahoo! Finance Canada
Viatris CFO leaving Canonsburg pharma giant - MSN
Barclays Adjusts Price Target on Viatris to $22 From $17, Maintains Overweight Rating - Moomoo
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain - Sahm
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Me - GuruFocus
TrumpRx expands into generic medicines (VTRS:NASDAQ) - Seeking Alpha
1.94%
자본화:
|
볼륨(24시간):